US FDA and PATH-MVI collaborate

The US Food and Drug Administration has announced a collaboration with the PATH Malaria Vaccine Initiative to develop laboratory tests to better predict the level of safety and effectiveness of experimental malaria vaccines before they are used in human clinical trials.

"This collaboration with the PATH-MVI supports the overall mission of the FDA and specifically the agency's work under our Critical Path Initiative," said Jesse Goodman, Director of the FDA's Center for Biologics Evaluation and Research, adding: "we are actively seeking ways to help organizations such as PATH develop safe and effective products that can benefit the public health both in the USA and globally."